Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Marsh, L. Articles by Reich, S. G. Search for Related Content PubMed Citation Articles by Marsh, L. Articles by Reich, S. G. Alzheimer's Disease

Olanzapine for the Treatment of Psychosis in Patients With Parkinson's Disease and Dementia

Received February 27, 2001; revised June 28, 2001; accepted July 19, 2001. From the Morris K. Udall Parkinson's Disease Research Center of Excellence at Johns Hopkins, the Neuropsychiatry Service, Department of Psychiatry and Behavioral Sciences, and the Movement Disorders Center, Department of Neurology, Johns Hopkins University School of Medicine, Johns Hopkins University, Baltimore, MD. Address correspondence and reprint requests to Dr. Marsh, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 600 N Wolfe St. Baltimore, MD 21287.

Psychotic symptoms are a common complication in Parkinson's disease with dementia. The authors conducted an open-label 6-week trial of olanzapine preceded by a placebo lead-in in five subjects with Parkinson's disease, mild to moderately severe dementia, and psychosis. Four of the subjects terminated the trial early because of worsening motor function, sedation, or paranoia. There was no improvement in psychotic symptoms, and functional abilities declined significantly. Olanzapine appears to be poorly tolerated in patients with Parkinson's disease, psychotic symptoms, and dementia.

Key Words: Dementia • Psychosis • Parkinson's Disease

This article has been cited by other articles:

				U. Lertxundi, J. Peral, O. Mora, S. Domingo-Echaburu, M. J. Martinez-Bengoechea, and J. C. Garcia-Monco Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease Am. J. Health Syst. Pharm., March 1, 2008; 65(5): 414 - 419. [Abstract] [Full Text] [PDF]

				References PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2. [Full Text]

				M. L. Onor, M. Saina, and E. Aguglia Efficacy and Tolerability of Quetiapine in the Treatment of Behavioral and Psychological Symptoms of Dementia American Journal of Alzheimer's Disease and Other Dementias, January 1, 2007; 21(6): 448 - 453. [Abstract] [PDF]

				N. Hoeh, L. Gyulai, D. Weintraub, and J. Streim Pharmacologic Management of Psychosis in the Elderly: A Critical Review J Geriatr Psychiatry Neurol, December 1, 2003; 16(4): 213 - 218. [Abstract] [PDF]

				I. Tofler Olanzapine and Neuroleptic Malignant Syndrome Psychosomatics, December 1, 2002; 43(6): 505 - 506. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2001 Academy of Psychosomatic Medicine. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us